Survival factors in lung cancer patients with mutations in the PROS1, SERPINC1, F2, and F5 genes.
- 1The Medical College of Georgia at Augusta University, Augusta, GA 30912, USA
- 2Department of Medicine, Division of Hematology and Oncology, Medical College of Georgia at Augusta University, Augusta, GA 30912, USA
Abstract
Copyright: © 2026 Brownlee et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.Purpose
Thrombophilia genes contribute to tumorigenesis and thrombotic events in lung cancer, yet current treatments do not incorporate gene-specific strategies for F2, F5, PROS1, and SERPINC1. We evaluated survival in lung cancer patients with thrombophilia mutations.Materials and methods
We queried TCGA-LUAD and TCGA-LUSC for primary lung cancers with F2, F5, PROS1, or SERPINC1 mutations. STAR RNA-seq expression was included in univariate and multivariate Cox models comparing patients with versus without thrombophilia mutations, adjusting for age, race, AJCC stage, primary site, treatment type, laterality, and treatment modalities. Hazard ratios with 95% confidence intervals were calculated.Results
We identified 569 patients with thrombophilia mutations and 850 without. Across all mutations, higher pathologic stage and right-sided tumors were associated with worse survival. F5 mutations were significantly associated with survival in middle-lobe (HR 1.49, p = 0.028), pleural (HR 1.33, p = 0.006), and upper-lobe (HR 1.20, p = 0.025) cancers. SERPINC1 and PROS1 mutations were associated with improved survival in upper-lobe cancers. Among upper-lobe cancers, African American patients with F5 mutations had worse survival by age at diagnosis (HR 1.01, p = 0.015) and race (HR 1.33, p = 0.024).Conclusions
Thrombophilia mutations influence lung cancer survival and may help refine gene-targeted therapies.
Related
- Survival Outcomes in Metastatic Colorectal Cancer Patients with BRAF Mutations Undergoing Targeted Chemotherapy: A Reconstructed Individual Patient Data Meta-Analysis of Randomized Controlled Trials.
- Cancer-Specific Survival in Octogenarian Breast Cancer Patients: A Competing Risk Analysis of Prognostic Factors.
- Cancer type-specific profiling of chromatin regulator mutations identifies recurrent and co-occurring gene sets associated with improved survival following immune checkpoint therapy
- Clinicopathological and Perioperative Factors Associated with Overall Survival and 90-Day Mortality Following Esophagectomy for Esophageal Cancer
- Development and internal validation of a prognostic model for cancer-specific survival in elderly patients with metastatic non-small cell lung cancer: a SEER-based study
BibTeX
@article{brownlee2026survival,
title = {{Survival factors in lung cancer patients with mutations in the PROS1, SERPINC1, F2, and F5 genes.}},
author = {Ryan Brownlee and Aditya Birla and Hung Bui and Raniya Ahmad and Dongyu Zhang and Andrew Ji and Girindra Raval},
journal = {Oncotarget},
year = {2026},
month = nov,
doi = {10.18632/oncotarget.28914},
url = {https://europepmc.org/article/MED/42969578},
note = {CC BY},
}
RIS
TY - JOUR
TI - Survival factors in lung cancer patients with mutations in the PROS1, SERPINC1, F2, and F5 genes.
AU - Ryan Brownlee
AU - Aditya Birla
AU - Hung Bui
AU - Raniya Ahmad
AU - Dongyu Zhang
AU - Andrew Ji
AU - Girindra Raval
PY - 2026
DA - 2026/11/01
JO - Oncotarget
DO - 10.18632/oncotarget.28914
UR - https://europepmc.org/article/MED/42969578
AB - Copyright: © 2026 Brownlee et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.Purpose Thrombophilia genes contribute to tumorigenesis and thrombotic events in lung cancer, yet current treatments do not incorporate gene-specific strategies for F2, F5, PROS1, and SERPINC1. We evaluated survival in lung cancer patients with thrombophilia mutations.Materials and methods We queried TCGA-LUAD and TCGA-LUSC for primary lung cancers with F2, F5, PROS1, or SERPINC1 mutations. STAR RNA-seq expression was included in univariate and multivariate Cox models comparing patients with versus without thrombophilia mutations, adjusting for age, race, AJCC stage, primary site, treatment type, laterality, and treatment modalities. Hazard ratios with 95% confidence intervals were calculated.Results We identified 569 patients with thrombophilia mutations and 850 without. Across all mutations, higher pathologic stage and right-sided tumors were associated with worse survival. F5 mutations were significantly associated with survival in middle-lobe (HR 1.49, p = 0.028), pleural (HR 1.33, p = 0.006), and upper-lobe (HR 1.20, p = 0.025) cancers. SERPINC1 and PROS1 mutations were associated with improved survival in upper-lobe cancers. Among upper-lobe cancers, African American patients with F5 mutations had worse survival by age at diagnosis (HR 1.01, p = 0.015) and race (HR 1.33, p = 0.024).Conclusions Thrombophilia mutations influence lung cancer survival and may help refine gene-targeted therapies.
SN - 1949-2553
ER -